AstraZeneca Pioneers U.K. Program Of Investigator-Led Studies For Novel Cancer Drug Combinations
This article was originally published in The Pink Sheet Daily
AstraZeneca is the first company to enter into a research agreement with a new alliance, formed by academia, the charity Cancer Research UK and the pharmaceutical industry, that aims to accelerate development of new anticancer combination therapies.
You may also be interested in...
Right Dosing, Scheduling Key To Anticipating Resistance, Creating Synergistic Combos In Drug Development
The art of developing synergistic combinations of novel drugs that can win the race against resistance mutations was much discussed at the American Association for Cancer Research meeting in Chicago March 31 - April 4.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Alexion/AstraZeneca has announced positive top-line results from the Phase III study of ALXN1840 in patients with the rare genetic disorder, Wilson disease, including in patients already on standard-of-care therapies. The compound is ahead of two candidate gene therapies from other companies at early-stage clinical development.